Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Q-linea ABCHIX:QLINES 64 Debt-to-Equity is 0.04 as of Jun. 2026, which is at its 10-year median of 0.04. GuruFocus rates CHIX:QLINES with a GF Score™ of 64/100 and a GF Value™ of kr1,905.81. The stock has 3 warning signs investors should review. Among 705 Medical Devices & Instruments companies, Q-linea AB ranks better than 85.39% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Q-linea AB's Debt-to-Equity or its related term are showing as below:
CHIX:QLINEs'
s Debt-to-Equity Range Over the Past 10 Years
Min: -5.51 Med: 0.04 Max: 3.6
Current: 0.04
During the past 11 years, the highest Debt-to-Equity Ratio of Q-linea AB was 3.60. The lowest was -5.51. And the median was 0.04.
CHIX:QLINEs's Debt-to-Equity is ranked better than 85.39% of 705
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs CHIX:QLINEs: 0.04
Q-linea AB (CHIX:QLINEs) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Q-linea AB Debt-to-Equity Related Terms
Q-linea AB Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Q-linea AB's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:QLINES vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, Q-linea AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-linea AB Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-linea AB's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Q-linea AB's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-linea AB (CHIX:QLINES) has a Debt-to-Equity of 0.04 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Q-linea AB and its competitors. This is near median its historical median of 0.04. According to the industry distribution chart, Q-linea AB ranks #103 out of 705 companies in the Medical Devices & Instruments industry, placing it in the top 14.6%.
Is Q-linea AB's Debt-to-Equity too high?
Q-linea AB's current Debt-to-Equity of 0.04 is near median its 10-year median of 0.04. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Q-linea AB's value of 0.04 is 82.6% below this industry median. Based on the distribution chart, Q-linea AB ranks #103 out of 705 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Q-linea AB has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Q-linea AB's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-linea AB ranks #103 out of 705 companies for Debt-to-Equity. This places Q-linea AB in the top 15% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.23. Q-linea AB's value of 0.04 is 82.6% below this benchmark. While the company's 10-year median is 0.04 vs. the industry median of 0.23, Q-linea AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Q-linea AB's current Debt-to-Equity of 0.04 is 82.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Q-linea AB and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-linea AB's current Debt-to-Equity is 0.04, which is near median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-linea AB stock overvalued right now?
Q-linea AB (CHIX:QLINES) has a current Debt-to-Equity of 0.04. The stock's GF Value™ is kr1,905.81, compared to a current price of kr1,610.00 — trading 15.5% below its estimated fair value. The current Debt-to-Equity is 0.04, which is near median its 10-year median of 0.04 and 82.6% below the Medical Devices & Instruments industry median of 0.23. Q-linea AB's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Q-linea AB (CHIX:QLINES), the current Debt-to-Equity is 0.04 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Q-linea AB (CHIX:QLINES) Overvalued in 2026?
Based on GuruFocus' analysis, Q-linea AB stock appears to be undervalued.
The current stock price of kr1,610.00 is trading 15.5% below its estimated GF Value™ of kr1,905.81.
Key valuation signals for CHIX:QLINES:
Debt-to-Equity: 0.04 (near median its 10-year median of 0.04)
GF Value™: kr1,905.81 vs. price of kr1,610.00 (15.5% below fair value)
Industry Position: 82.6% below the Medical Devices & Instruments median (#103 of 705)
No single metric tells the full story. See the CHIX:QLINES stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.
64GF Score
Get the complete analysis for CHIX:QLINES
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:QLINES has been successfully added to your 
